Anbio Biotechnology
NNNN Nasdaq
SEC CIK 1982708
Follow Anbio Biotechnology
Weekly email: filings, results
EPS, diluted
-
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $8.6M | $6.4M |
| FY24 | $8.2M | $2.4M |
| FY23 | $6.7M | $2.3M |
| FY22 | $23.5M | $10M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 87.2% | 66.7% | 74.1% |
| FY24 | 71.9% | 24.4% | 29% |
| FY23 | 50.1% | 29.2% | 33.6% |
| FY22 | 53.4% | 43.3% | 42.5% |
- Anbio Biotechnology
- Healthcare median
Show the numbers
| Year | Anbio Biotechnology | Healthcare median |
|---|---|---|
| FY25 | 74.1% | −30.6% |
| FY24 | 29% | −47% |
| FY23 | 33.6% | −58% |
| FY22 | 42.5% | −80.4% |